---
title: "12 Health Care Stocks Moving In Wednesday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292819613.md"
description: "During Wednesday's after-market session, several healthcare stocks experienced significant volatility. Gainers included Agape ATP (+17.5%), China Pharma Holding (+14.52%), and GlucoTrack (+10.56%). Conversely, losers featured Exicure (-10.5%), Omada Health (-8.74%), and SciSparc (-7.76%). Evogene dropped 5.75% following its FY earnings report, while ORIC Pharmaceuticals fell 5.57%. Market caps ranged from $2.0 million to $1.3 billion across these movers."
datetime: "2026-07-15T21:05:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292819613.md)
  - [en](https://longbridge.com/en/news/292819613.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292819613.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Wednesday's After-Market Session

### Gainers

-   **Agape ATP** (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million.
-   **China Pharma Holding** (AMEX:CPHI) stock increased by 14.52% to $1.26. The company's market cap stands at $24.9 million.
-   **GlucoTrack** (NASDAQ:GCTK) shares increased by 10.56% to $0.58. The company's market cap stands at $3.3 million.
-   **Barinthus Biotherapeutics** (NASDAQ:BRNS) stock rose 8.14% to $0.7. The company's market cap stands at $25.0 million.
-   **Catheter Precision** (AMEX:VTAK) stock moved upwards by 6.94% to $0.62. The market value of their outstanding shares is at $2.0 million.
-   **Artelo Biosciences** (NASDAQ:ARTL) shares moved upwards by 6.08% to $1.22. The market value of their outstanding shares is at $4.0 million.

### Losers

-   **Exicure** (NASDAQ:XCUR) stock declined by 10.5% to $1.45 during Wednesday's after-market session. The company's market cap stands at $10.9 million.
-   **Omada Health** (NASDAQ:OMDA) stock declined by 8.74% to $21.66. The company's market cap stands at $1.3 billion.
-   **SciSparc** (NASDAQ:SPRC) shares decreased by 7.76% to $4.52. The company's market cap stands at $2.4 million.
-   **Alpha Compute** (NASDAQ:ALP) shares decreased by 7.53% to $0.29. The company's market cap stands at $7.8 million. As per the news, the FY earnings report came out today.
-   **Evogene** (NASDAQ:EVGN) stock decreased by 5.75% to $0.55. The company's market cap stands at $5.8 million.
-   **ORIC Pharmaceuticals** (NASDAQ:ORIC) stock fell 5.57% to $10.52. The company's market cap stands at $1.0 billion. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ATPC.US](https://longbridge.com/en/quote/ATPC.US.md)
- [SPRC.US](https://longbridge.com/en/quote/SPRC.US.md)
- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [EVGN.US](https://longbridge.com/en/quote/EVGN.US.md)
- [ORIC.US](https://longbridge.com/en/quote/ORIC.US.md)
- [OMDA.US](https://longbridge.com/en/quote/OMDA.US.md)
- [XCUR.US](https://longbridge.com/en/quote/XCUR.US.md)
- [CPHI.US](https://longbridge.com/en/quote/CPHI.US.md)
- [BRNS.US](https://longbridge.com/en/quote/BRNS.US.md)
- [VTAK.US](https://longbridge.com/en/quote/VTAK.US.md)
- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)
- [ALP.US](https://longbridge.com/en/quote/ALP.US.md)

## Related News & Research

- [GlucoTrack unit Lokahi Therapeutics starts GMP manufacturing for LT-100 osteoarthritis pain candidate](https://longbridge.com/en/news/296910729.md)
- [GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia](https://longbridge.com/en/news/296614954.md)
- [ISS, Glass Lewis urge Evogene shareholders to back management slate over dissidents seeking board overhaul at Sept. 4 vote](https://longbridge.com/en/news/296901808.md)
- [Scisparc posts audited 2025 net loss of USD 12.56 million](https://longbridge.com/en/news/296357022.md)
- [GlucoTrack Shareholders Approve Key Governance and Capital Actions](https://longbridge.com/en/news/296385751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**